Navigation Links
Arrowhead Subsidiaries Insert & Calando Present Data on,Cyclosert Drug Delivery System at AACR Meeting

ancer cell lines. The conjugate was found to be stable and 100 times more water soluble than the free drug.

Calando's Chief Scientific Officer, Jeremy Heidel, Ph.D, will present data from animal studies using the Cyclosert system augmented by Calando's own proprietary technology. Calando is developing a type of ribonucleic acid (RNA) called small interfering RNA, or siRNA, for anticancer use. In the tests, this siRNA-containing formulation, using Cyclosert as a delivery system, showed significant antitumor activity and was well-tolerated.

Testing and development is ongoing for both drugs.

About Arrowhead Research Corporation

Arrowhead Research Corporation (www.arrowheadresearch.com) is a leading nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials.

About Insert Therapeutics Inc.

Insert Therapeutics, Inc. (www.insertt.com) is using its proprietary, nano-engineered, polymeric delivery system, Cyclosert(TM), to design, develop and commercialize drug-delivery-enhanced small-molecule therapeutics and nucleic acids. Cyclosert uses cyclodextrins as building blocks to create an entirely new class of biocompatible materials -- linear cyclodextrin-containing polymers that are non-toxic and non-immunogenic at therapeutic doses. The company i
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from Human Clinical Trials for New Cancer Drug
2. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
3. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
4. Dharma Therapeutics Shows IDDS Is Effective in Reducing Pain Associated With Insertion of an Intravenous Catheter in Their Phase 2 Clinical Trial
5. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
6. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
7. Vastox Awarded £400,000 Grant to Support R&D at Carbohydrate Chemistry Facility
8. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
9. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
10. Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years
11. Calando Pharmaceuticals Announces Preclinical Efficacy and Safety Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting
Post Your Comments:
(Date:12/1/2008)...EGO, Dec. 1 TargeGen has announced...s from a multi-center, US-based clinical,trial of...as been scheduled at,the 2008 American Society of...he presentation are as follows:, Title: ...oavailable, JAK2-Selective...
(Date:12/1/2008)...APOLIS, Dec. 1 Roche announced tod... differences in perceived pain and,discomfort ass...K blood,glucose monitoring systems and lancing de...indicated that, overall, the ACCU-CHEK Aviva and A...stems and the ACCU-CHEK Multiclix, ACCU-CHEK,Soft...
(Date:12/1/2008)...de study shows the Prox1 gene is a two-way switch ...cells to be reprogrammed so that they lose their i...ls , , MEMPHIS, Tenn., Dec. 1 /PRNewswire-U...esearch Hospital have discovered that a certain di...dentity that it requires the constant expression o...
(Date:12/1/2008)...TH MEETING, Pa., Dec. 1 ...nced that dosing of subjects has begun in study MS...se Phase 1b study of trodusquemine (MSI-1436) in o...a novel therapeutic for the treatment of type 2 di...herally to regulate insulin and leptin pathways th...
Breaking Medicine Technology:Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 2Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 3Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3Embryos Discarded During IVF Create Stem Cell Lines 10220 1Embryos Discarded During IVF Create Stem Cell Lines 10220 2Cancer Vaccine Consortium and Cancer Vaccine Collaborative unite under the Cancer Research Institute 10218 1Cancer Vaccine Consortium and Cancer Vaccine Collaborative unite under the Cancer Research Institute 10218 2Cancer Vaccine Consortium and Cancer Vaccine Collaborative unite under the Cancer Research Institute 10218 3The Beryl Companies Introduces New Customer Service Call Offering for Hospitals Nationwide 10216 1The Beryl Companies Introduces New Customer Service Call Offering for Hospitals Nationwide 10216 2NutraCea Provides Update on Domestic Operations 10215 1NutraCea Provides Update on Domestic Operations 10215 2NutraCea Provides Update on Domestic Operations 10215 3
...atient Lung Cancer Diversity Study, CHICAGO, June ...,lung cancer is the leading cause of cancer death ...ed to be diagnosed,and 16,700 deaths expected this...leading cause of cancer death in Hispanic men and ...ic women.(ii),Researchers at Eli Lilly and Company...
...l CBR of 52% which compares favorably with,the act..., 2007 /PRNewswire-FirstCall/ - AEterna,Zentaris I...n,endocrine therapy and oncology, today announced ...ed a poster outlining Phase 1 and,Phase 2 results ...ction inhibitor compound, for the treatment of pat...
Other Medicine Technology:Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 2Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 3Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 4Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 5Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 6Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 7Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 8Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 9Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 10Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 11AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 2AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 3AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results,for Anti-Cancer Compound Perifosine at ASCO Meeting 4
(Date:12/2/2008)...o Celebrate With Traditional Holiday Cuisine , ... Food Ministries ( www.angelfoodministries.com ), ...y food at low-costs, to anyone who wishes to parti...include a specialty Christmas Box which includes e...tion. Host sites are now taking orders throughout ...
(Date:12/2/2008)...l Deficiencies in Care for Individuals across the ... Members who recently sought expert medical consul...certainty about their initial diagnosis or course ... , The findings are based on clinical review...s a unique health benefit that calls upon top medi...
(Date:12/2/2008)...ion Highlights Need to Reduce Disparities in Menin... , , BETHESDA, Md., Dec. 2 ... (NFID) S.T.O.P. (Share. Teach. Outreach. Protec...he nation,s leading medical and advocacy organizat...adolescent meningococcal vaccination rates and to ...
(Date:12/2/2008)...it could aid shift workers, people affected by jet...) -- The experimental drug tasimelteon helps treat...fts, according to the results of two new clinical ... randomly assigned to receive either 10 milligrams...ebo. They were monitored for seven nights -- three...
Breaking Medicine News(10 mins):Health News:Angel Food Ministries to Distribute Holiday Grocery Relief 2Health News:Consumers Uncertain About Their Medical Diagnosis & Treatment 2Health News:Consumers Uncertain About Their Medical Diagnosis & Treatment 3Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 2Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 3Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 4Health News:Drug Effective for Temporary Sleep Disruptions 2
...unfortunate instances we see couples who are HIV s...If the husband is HIV –1 positive and the wife is ... problem arises because sexual intercourse carries... female partner and through her to the fetus. Sper...
...e unlucky to be afflicted by the deadly chronic my... there's some good news. One of the deadliest fo... kills thousands across the globe. Chronic myel...und and still continues to be one. But there's go...
... medical practice of Acupuncture along with common...and disabling side effects of chemotherapy for bre...stitute of Health (NIH) are to be believed. Acco...search associate at NIH, electro-acupuncture was m...
... blood test can give clue if the heart attack pati...ogged vessels and restore blood flow to their hear...tt analyzed medical records of more than 12,000 he...tients whose white blood cell count is in what is ...
Other Medicine News:Health News:Sperm washing helps couples – Breakthrough in focu 2
Precision near-field imaging combined with the best handling IVUS catheter.
The Medison SonoAce 9900 is a fully digital, NT2000 based ultrasound system, with an integrated workstation that is DICOM compatible, designed for multi-specialty applications including general imagi
Full Digital Color Ultrasound
...armonic Echo technology constructs images using se...rtifacts and noise than fundamental-frequency comp...ogy to transmit distortion-free, fundamental-frequ...equency ultrasound beam is a pure sinusoidal wave,...
Medicine Products: